Crescent Biopharma, Inc. (CBIO) is a Biotechnology company in the Healthcare sector, currently trading at $19.52. It has a SharesGrow Score of 47/100, indicating a mixed investment profile with 1 out of 7 criteria passed.
Analyst consensus target is CBIO = $33 (+69.1% upside).
Valuation: CBIO trades at a trailing Price-to-Earnings (P/E) of -13.2 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 3.06.
Financials: revenue is $11M, +4346.9%/yr average growth. Net income is $150M (loss), growing at -29.5%/yr. Net profit margin is -1382.7% (negative). Gross margin is 99.2% (+99.8 pp trend).
Balance sheet: total debt is $2M against $203M equity (Debt-to-Equity (D/E) ratio 0.01, conservative). Current ratio is 6.56 (strong liquidity). Debt-to-assets is 0.7%. Total assets: $240M.
Analyst outlook: 9 / 13 analysts rate CBIO as buy (69%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 39/100 (Fail), Growth 58/100 (Partial), Past 25/100 (Fail), Health 67/100 (Partial), Moat 56/100 (Partial), Future 73/100 (Pass), Income 10/100 (Fail).
